Teriparatide in the acceleration of comminuted fracture

Phase 3

• Conditions: comminuted fracture union of tibia and femural shaft.

• Registration Number: IRCT20221220056874N1
• Lead Sponsor: Karaj University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

Having comminuted fractured tibia and femural shaft
Obtaining informed consent to participate in this study
Being between 18-45 years old
Not having osteoporosis that has been confirmed in the radiographies
Not being allergic to triparatide
If a person has previously used bisphosphonates, at least three months should pass after stopping their use, and then start triparatide.
Not having a serious underlying disease such as uncontrolled diabetes, heart failure, kidney failure, etc.
Not having Paget's disease, hypercalcemia for any reason, hyperparathyroidism
No history of osteosarcoma

Exclusion Criteria

Under 18 and over 45 years old
Allergy to triparatide
Having a serious underlying disease such as uncontrolled diabetes, heart failure, kidney failure, etc.
Having Paget's disease, hypercalcemia for any reason, hyperparathyroidism
Having a history of osteosarcoma

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
nion of comminuted fracture of tibia and femural shaft fracture. Timepoint: Every month after prescribing the drug for up to six months. Method of measurement: Clinical sign and symptoms and radiographic signs.